Li Xiaoqin, Shen Hesong, Peng Yangling, Miao Zhiming, Tu Chunrong, Zhang Xiaoyong, Wu Zhigang, Zeng Xiaohua, Zhang Jiuquan
Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.
Clinical Science, Philips Healthcare, Chengdu, China.
Eur J Radiol. 2024 Dec;181:111755. doi: 10.1016/j.ejrad.2024.111755. Epub 2024 Sep 24.
We aimed to describe changes in parameters derived from myocardial T1ρ, T1, and T2 mapping and assess whether incorporating T1ρ mapping improves the predictive performance of T1 and T2 mapping for subsequent cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients treated with anthracyclines with/without trastuzumab.
From March 2021 to May 2023, 82 participants with breast cancer treated with anthracyclines with/without trastuzumab were prospectively recruited. Cardiac magnetic resonance was performed at baseline, 3 and 6 months in relation to baseline. T1ρ, T1 and T2 values were measured and compared by repeated measures analyses of variance. Logistic regression and receiver operating characteristic analysis were used to assess the performance in predicting subsequent CTRCD.
Nineteen (23.17 %) participants developed CTRCD. T1ρ and T1 values progressively increased over time (all p < 0.001), while T2 values increased at 3 (p < 0.001 and p = 0.002, respectively) and 6 months (all p < 0.001) compared to baseline in both the CTRCD (+) and CTRCD (-) groups. The changes in T1ρ (OR, 3.892, p = 0.003) and T1 (OR, 1.082, p = 0.002) from baseline to 3 months were associated with subsequent CTRCD. The combination of the changes in T1ρ and T1 from baseline to 3 months obtained an improved area under the curve of 0.853.
T1ρ, T1 and T2 increased after treatment of anthracyclines with/without trastuzumab. Myocardial T1ρ mapping provides additional predictive value to T1 mapping for subsequent CTRCD in breast cancer patients who received anthracyclines with/without trastuzumab.
Myocardial T1ρ mapping offers additional predictive value to T1 and T2 mapping for subsequent CTRCD in breast cancer patients who received anthracyclines with/without trastuzumab. This may facilitate accurate prediction of cardiotoxicity and personalized treatment decision making in breast cancer.
我们旨在描述心肌T1ρ、T1和T2映射得出的参数变化，并评估纳入T1ρ映射是否能提高T1和T2映射对接受含或不含曲妥珠单抗的蒽环类药物治疗的乳腺癌患者后续癌症治疗相关心脏功能障碍（CTRCD）的预测性能。
2021年3月至2023年5月，前瞻性招募了82名接受含或不含曲妥珠单抗的蒽环类药物治疗的乳腺癌患者。在基线、相对于基线的3个月和6个月时进行心脏磁共振成像。通过重复测量方差分析测量并比较T1ρ、T1和T2值。使用逻辑回归和受试者工作特征分析来评估预测后续CTRCD的性能。
19名（23.17%）参与者发生了CTRCD。T1ρ和T1值随时间逐渐增加（所有p<0.001），而在CTRCD（+）组和CTRCD（-）组中，与基线相比，T2值在3个月时（分别为p<0.001和p = 0.002）以及6个月时（所有p<0.001）均增加。从基线到3个月时T1ρ（比值比，3.892，p = 0.003）和T1（比值比，1.082，p = 0.002）的变化与后续CTRCD相关。从基线到3个月时T1ρ和T1变化的组合获得了改善的曲线下面积，为0.853。
接受含或不含曲妥珠单抗的蒽环类药物治疗后，T1ρ、T1和T2升高。对于接受含或不含曲妥珠单抗的蒽环类药物治疗的乳腺癌患者，心肌T1ρ映射为T1映射对后续CTRCD提供了额外的预测价值。
对于接受含或不含曲妥珠单抗的蒽环类药物治疗的乳腺癌患者，心肌T1ρ映射为T1和T2映射对后续CTRCD提供了额外的预测价值。这可能有助于准确预测心脏毒性并在乳腺癌中进行个性化治疗决策。
